Veltassa is a drug owned by Vifor Pharma. Its active ingredient is patiromer sorbitex calcium. The drug was first authorized for market use on October 21, 2015, with a total of 13 patents, none of which have expired yet.
The generic version of Veltassa is likely to be released after the expiration of the last patent on October 8, 2033. The majority of Veltassa's patents extend into the late 2020s and early 2030s, and the generic release date will be determined by the last patent expiration.
Veltassa, containing the active ingredient patiromer sorbitex calcium, is used for the treatment of hyperkalemia, a condition characterized by elevated levels of potassium in the blood.
Veltassa holds 13 patents, the last of which is set to expire on October 8, 2033. Details of Veltassa's patents, including those titled 'Ion binding polymers and uses thereof' and 'Potassium-binding agents for treating hypertension and hyperkalemia', can be found below. The detailed overview provides insight into when we might see the release of Veltassa generic versions. Below are the details of the patent: